Geode Capital Management LLC Has $140.28 Million Stock Position in Repligen Co. (NASDAQ:RGEN)

Geode Capital Management LLC cut its holdings in Repligen Co. (NASDAQ:RGEN) by 0.3% during the 3rd quarter, HoldingsChannel reports. The fund owned 942,371 shares of the biotechnology company’s stock after selling 2,793 shares during the quarter. Geode Capital Management LLC’s holdings in Repligen were worth $140,278,000 as of its most recent filing with the SEC.

Other hedge funds have also bought and sold shares of the company. Assenagon Asset Management S.A. grew its position in shares of Repligen by 937.8% during the 2nd quarter. Assenagon Asset Management S.A. now owns 30,189 shares of the biotechnology company’s stock worth $3,806,000 after purchasing an additional 27,280 shares in the last quarter. Raymond James & Associates grew its position in Repligen by 3.7% during the second quarter. Raymond James & Associates now owns 55,119 shares of the biotechnology company’s stock worth $6,948,000 after buying an additional 1,951 shares in the last quarter. Fifth Third Bancorp increased its stake in Repligen by 6.4% during the 2nd quarter. Fifth Third Bancorp now owns 3,096 shares of the biotechnology company’s stock worth $390,000 after acquiring an additional 187 shares during the period. Fifth Third Wealth Advisors LLC acquired a new position in Repligen in the 2nd quarter valued at $273,000. Finally, Slow Capital Inc. lifted its position in shares of Repligen by 10.7% during the 2nd quarter. Slow Capital Inc. now owns 16,165 shares of the biotechnology company’s stock valued at $2,038,000 after acquiring an additional 1,558 shares during the period. 97.64% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

RGEN has been the subject of a number of analyst reports. Wolfe Research began coverage on Repligen in a research note on Thursday, November 14th. They issued a “peer perform” rating for the company. Royal Bank of Canada restated an “outperform” rating and issued a $205.00 target price on shares of Repligen in a research report on Thursday, September 26th. Wells Fargo & Company assumed coverage on shares of Repligen in a research report on Tuesday, August 27th. They set an “overweight” rating and a $180.00 price target on the stock. Finally, StockNews.com upgraded shares of Repligen from a “sell” rating to a “hold” rating in a research report on Friday, November 22nd. Four research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, Repligen has a consensus rating of “Moderate Buy” and an average target price of $190.25.

Repligen Stock Performance

Repligen stock opened at $160.92 on Tuesday. The business has a 50 day moving average of $142.66 and a 200-day moving average of $141.59. The company has a market capitalization of $9.02 billion, a P/E ratio of -434.92, a P/E/G ratio of 4.64 and a beta of 0.96. Repligen Co. has a 1 year low of $113.50 and a 1 year high of $211.13. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76.

Repligen (NASDAQ:RGEN) last released its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.34 by $0.09. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. The firm had revenue of $154.87 million during the quarter, compared to the consensus estimate of $153.34 million. During the same quarter last year, the firm earned $0.23 earnings per share. The company’s revenue for the quarter was up 9.7% on a year-over-year basis. On average, equities research analysts predict that Repligen Co. will post 1.54 earnings per share for the current year.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.